🔎 Trials Near Me

Почетна › Немалоклетни карцином плућа › Florida › Gainesville

Kliničke studije za Немалоклетни карцином плућа u gradu Gainesville, FL

11 studija za Немалоклетни карцином плућа traži učesnike na lokacijama u gradu Gainesville i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.

Zvanični tekst studije (na engleskom)

Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Тражи се учесникФаза 3
  • Malcom Randall Veterans Administration Medical Center, Gainesville
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT04267848

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

Тражи се учесникФаза 3
  • UF Health Cancer Center ( Site 3257), Gainesville
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT07513376

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Тражи се учесникФаза 3
  • University of Florida Health at Shands, Gainesville
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06793215

Universal Immunization to Fortify Immunotherapy Efficacy and Response

Тражи се учесникФаза 2
  • University of Florida, Gainesville
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT07597070

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Тражи се учесникФаза 3
  • Research Site, Gainesville
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06692738

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Тражи се учесникФаза 3
  • Research Site, Gainesville
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT06357533

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Тражи се учесникФаза 2
  • Malcom Randall Veterans Administration Medical Center, Gainesville
Узраст 18 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT06116682

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Тражи се учесникФаза 2/3
  • Malcom Randall Veterans Administration Medical Center, Gainesville
Узраст 18 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT06616584

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Тражи се учесникФаза 3
  • Florida Cancer Specialists, Gainesville
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT07222566

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Тражи се учесникФаза 1
  • Exelixis Clinical Site #11, Gainesville
Узраст 18 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT05176483

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Тражи се учесникФаза 3
  • Research Site, Gainesville
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2026. · NCT06868277

Studije za Немалоклетни карцином плућа u drugim gradovima

Ostale studije u gradu Gainesville

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.